Vanderbilt University Medical Center is recruiting participants for the Phase 3 Hunger Elimination or Reduction Objective ...

When 15-year-old Anna Hankins accepted the title of Miss Amazing in Chicago, the Mississippi teen was beaming not only because of the award, but also because of the opportunity to raise awareness ...

How Does It Work for Excessive Hunger? Prader-Willi syndrome is a rare condition usually caused by genetic changes in your DNA. It can also occur after a head or brain injury. The condition affects ...

Juliana Steffan's mother, April Steffan, created a YouTube video about Prader-Willi syndrome, a rare genetic disorder that causes a chronic feeling of hunger, among other physical, mental and ...

In a comprehensive Genomic Press Invited Expert Review, researchers from the University of Haifa have synthesized cutting-edge findings on Prader-Willi syndrome (PWS), revealing how this complex ...

POMONA ‒ When you fill up through October at the Mt. Ivy Country Corner's Shell gas pumps, a slice of the profits will go to helping kids like 3-year-old Catalina Valenti, who lives with Prader-Willi ...

The latest jump in Rhythm Pharmaceuticals (RYTM) shares is tied directly to encouraging preliminary Phase 2 data for setmelanotide in Prader Willi syndrome, where patients showed reductions in both ...

Rhythm Pharma (RYTM) added ~15% on Thursday after the company announced plans to advance its lead asset, setmelanotide, into a registrational Phase 3 trial for a rare genetic disorder called ...

The Boston-based pharmaceutical company said the Phase 2 trial showed that setmelanotide was effective in reducing body mass index and hyperphagia in patients with Prader-Willi syndrome, a genetic ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of the Phase 3 COMPASS PWS study evaluating the efficacy and safety of carbetocin nasal spray (ACP ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin ...